Neuropeptides
Volume 44, Issue 3 , Pages 279-283 , June 2010

Suppressive effects by cysteine protease inhibitors on naloxone-precipitated withdrawal jumping in morphine-dependent mice

  • Koichi Tan-No

      Affiliations

    • Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan
    • Corresponding Author InformationCorresponding author. Tel./fax: +81 22 727 0123.
    • ,
  • Tasuku Sato

      Affiliations

    • Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan
    • ,
  • Masakazu Shimoda

      Affiliations

    • Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan
    • ,
  • Osamu Nakagawasai

      Affiliations

    • Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan
    • ,
  • Fukie Niijima

      Affiliations

    • Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan
    • ,
  • Shunsuke Kawamura

      Affiliations

    • Educational Center for Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan
    • ,
  • Seiichi Furuta

      Affiliations

    • Division of Community Health Care, Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka, Otaru 047-0264, Japan
    • ,
  • Takumi Sato

      Affiliations

    • Department of Pharmacology and Pharmacotherapy, Nihon Pharmaceutical University, Kitaadachi-gun, Saitama 362-0806, Japan
    • ,
  • Susumu Satoh

      Affiliations

    • Department of Pharmacology and Pharmacotherapy, Nihon Pharmaceutical University, Kitaadachi-gun, Saitama 362-0806, Japan
    • ,
  • Jerzy Silberring

      Affiliations

    • Department of Biochemistry and Neurobiology, AGH University of Science and Technology, Krakow, Poland
    • ,
  • Lars Terenius

      Affiliations

    • Department of Clinical Neuroscience, Section of Alcohol and Drug Dependence Research, Karolinska Institute, Stockholm S-171 76, Sweden
    • ,
  • Takeshi Tadano

      Affiliations

    • Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan

Received 6 August 2009 ,Accepted 4 February 2010.

References 

  1. Clark JA, Liu L, Price N, Hersh B, Edelson M, Pasternak GW. Kappa opioid receptor multiplicity: evidence for two U50, 488H-sensitive κ1 subtypes and a novel κ3 subtypes. Journal of Pharmacology and Experimental Therapeutics. 1989;251:461–468
  2. Höllt V. Opioid peptide processing and receptor selectivity. Annual Review of Pharmacology and Toxicology. 1986;26:59–77
  3. Hooke LP, He L, Lee NM. Dynorphin A modulates acute and chronic opioid effects. Journal of Pharmacology and Experimental Therapeutics. 1995;273:292–297
  4. Maldonado R, Dauge V, Callebert J, Villette JM, Fournie-Zaluski M-C, Feger J, et al. Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine withdrawal syndrome. European Journal of Pharmacology. 1989;165:199–207
  5. Meng F, Xie G, Thompson R, Mansour A, Goldstein A, Watson S, et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:9954–9958
  6. Nagase H, Hayakawa J, Kawamura K, Kawai K, Takezawa Y, Matsuura H, et al. Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan. Chemical and Pharmaceutical Bulletin. 1998;46:366–369
  7. Noda Y, Nabeshima T. Opiate physical dependence and N-methyl-d-aspartate receptors. European Journal of Pharmacology. 2004;500:121–128
  8. Pan Y-X, Cheng J, Xu J, Rossi G, Jacobson E, Ryan-Moro J, et al. Cloning and functional characterization through antisense mapping of a κ3-related opioid receptor. Molecular Pharmacology. 1995;47:1180–1188
  9. Persson S, Post C, Alari L, Nyberg F, Terenius L. Increased neuropeptide-converting enzyme activities in cerebrospinal fluid of opiate-tolerant rats. Neuroscience Letters. 1989;107:318–322
  10. Silberring J, Nyberg F. A novel bovine spinal cord endoprotease with high specificity for dynorphin B. Journal of Biological Chemistry. 1989;264:11082–11086
  11. Silberring J, Castello ME, Nyberg F. Characterization of dynorphin A-converting enzyme in human spinal cord. An endoprotease related to a distinct conversion pathway for the opioid heptadecapeptide?. Journal of Biological Chemistry. 1992;267:21324–21328
  12. Silberring J, Demuth H-U, Brostedt P, Nyberg F. Inhibition of dynorphin converting enzymes from human spinal cord by N-peptidyl-O-acyl hydroxylamines. Journal of Biochemistry. 1993;114:648–651
  13. Takemori AE, Loh HH, Lee NM. Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. European Journal of Pharmacology. 1992;221:223–226
  14. Takemori AE, Loh HH, Lee NM. Suppression by dynorphin A and [Des-Tyr1]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. Journal of Pharmacology and Experimental Therapeutics. 1993;266:121–124
  15. Tan-No K, Taira A, Sakurada T, Inoue M, Sakurada S, Tadano T, et al. Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test. European Journal of Pharmacology. 1996;314:61–67
  16. Tan-No K, Ohshima K, Taira A, Inoue M, Niijima F, Nakagawasai O, et al. Antinociceptive effect produced by intracerebroventricularly administered dynorphin A is potentiated by p-hydroxymercuribenzoate or phosphoramidon in the mouse formalin test. Brain Research. 2001;891:274–280
  17. Tan-No K, Taira A, Nakagawasai O, Niijima F, Demuth H-U, Silberring J, et al. Differential effects of N-peptidyl-O-acyl hydroxylamines on dynorphin-induced antinociception in the mouse capsaicin test. Neuropeptides. 2005;39:569–573
  18. Tan-No K, Shimoda M, Sugawara M, Nakagawasai O, Niijima F, Watanabe H, et al. Cysteine protease inhibitors suppress the development of tolerance to morphine antinociception. Neuropeptides. 2008;42:239–244
  19. Tan-No K, Shimoda M, Watanabe K, Nakagawasai O, Niijima F, Kanno S, et al. Involvement of the p53 tumor-suppressor protein in the development of antinociceptive tolerance to morphine. Neuroscience Letters. 2009;450:365–368
  20. Tsuji M, Takeda H, Matsumiya T, Nagase H, Yamazaki M, Narita M, et al. A novel κ-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sciences. 2000;66:PL353–PL358
  21. Ueda H, Inoue M, Takeshima H, Iwasawa Y. Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence. The Journal of Neuroscience. 2000;20:7640–7647
  22. Vlaskovska M, Nylander I, Schramm M, Hahne S, Kasakov L, Silberring J, et al. Opiate modulation of dynorphin conversion in primary cultures of rat cerebral cortex. Brain Research. 1997;760:85–93
  23. Zukin RS, Eghbali M, Olive D, Unterwald EM, Tempel A. Characterization and visualization of rat and guinea pig brain κ opioid receptors: evidence for κ1 and κ2 opioid receptors. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:4061–4065

PII: S0143-4179(10)00008-9

doi: 10.1016/j.npep.2010.02.001

Neuropeptides
Volume 44, Issue 3 , Pages 279-283 , June 2010

Article Tools

* Image Usage & Resolution